The Desmond Tutu
HIV Foundation

Pairing rigorous research with community-driven development, the DTHF is making a substantial contribution to service delivery and public health policy relating to HIV, tuberculosis and related infections in South Africa.

About Us Our People

HIV weekly news update in partnership with MedicalBrief

  • MEDICALBRIEF Issue No 0195 – HIV News 15 March 2018

    Adverse pregnancy outcomes with Isoniazid Preventive Therapy in HIV

    Isoniazid preventive therapy (IPT) for tuberculosis in pregnant women with HIV is associated with excess adverse pregnancy outcomes and may warrant a re-assessment of the current WHO and the CDC guidelines.
  • MEDICALBRIEF Issue No 0195 – HIV News 15 March 2018

    Statins lower cancer risk in both HIV-positive and HIV-negative people

    Both HIV-positive and HIV-negative people who use statins to manage cardiovascular disease risk also have a lower risk of cancer.
  • MEDICALBRIEF Issue No 0195 – HIV News 15 March 2018

    Sub-optimal immune recovery on antiretroviral therapy

    A subset of people on ART experience limited or no recovery of CD4+ T cell counts despite achieving and maintaining undetectable HIV viral loads, and these individuals have an elevated risk of illness and death compared with counterparts who obtain greater CD4+ T cell gains.
  • MEDICALBRIEF Issue No 0194 – HIV News 08 March 2018

    Dolutegravir at 50mg twice daily is safe and effective in patients on TB treatment

    Data presented at CROI 2018 in Boston from the 24-week interim analysis of the INSPIRING clinical trial showed that dolutegravir administered at 50mg twice-daily with dual nucleoside reverse transcriptase inhibitors (NRTI), was effective and well-tolerated in HIV/TB co-infected adults receiving rifampin-based TB therapy.
  • MEDICALBRIEF Issue No 0194 – HIV News 08 March 2018

    One-month TB prophylaxis as effective as 9-month regimen for people living with HIV

    A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.
View All

Our Research


Results from innovative tuberculosis vaccine trial show potential for new BCG revaccination strategies and hope for subunit vaccines.

Scientists from the South African Tuberculosis Vaccine Initiative (SATVI) based at the University of Cape Town and the Desmond Tutu …
Read More

Measuring Early Treatment Adherence (META) Study: What We Found

The DTHF team at the Gugulethu Research Offices (GRO) under the direction of local Principal Investigator, Assoc Professor Catherine Orrell, …
Read More

20,000 Moments Condoms Donated to Women of Worth

Many young South Africans do not know that contraceptives are available. The shipment of more than 20 000 Coral Healthcare condoms has …
Read More

Apply for the Mark Wainberg Fellowship Opportunity for Clinicians

The Mark Wainberg Fellowship Programme: Experts in HIV Service Delivery is a two-year fellowship for five sub-Saharan African clinicians. This …
Read More

Our Projects

Desmond Tutu HIV Centre: Postgraduate Diploma in TB-HIV Medicine

Overview The Desmond Tutu HIV Centre and the University of Cape Town are proud to present the first online postgraduate …
Read More

The Tutu Tester

HIV and TB are managed successfully in many countries around the world. Yet, millions of people are still missing care. …
Read More

Adult HIV Educational Programme

Order a Manual Free Online Manual The aim of the HIV education programme is to improve the care of men …
Read More


Youth Centre
Youth Centre

The DTHF Youth Centre

The DTHF Youth Centre complex in Masiphumelele was built in response to requests from the community for a safe, recreational space for young people. DTHF surveys record a high prevalence of HIV infection among youth in the community.

Visit the Youth Centre